Who We Are
ACT Genomics is an internationally recognized award-winning cancer solution provider. Combining our expertise in the fields of cancer genomics and bioinformatics with our cutting-edge technologies, we are able to assist medical practitioners and scientists with genomics-driven recommendations and data for cancer treatment strategy and discovery.
Our Management Team
What We Oﬀer
Comprehensive genomic proﬁling allows your doctor to use the results to optimize a treatment plan for you. This approach is known as "precision medicine".
For Medical Professionals
A selection of genomic testing services for major solid tumor types handled through our CAP-accredited laboratory. Our results are delivered within a short TAT for timely treatment planning.
Assistance in biomarker discovery and companion diagnostic development by leveraging our cancer genomics databases and know-how. Shorten the process of drug development to commercial launch.
For Research Institutes
Detection and extrapolation of a potential cancer biomarker target by performing deep sequencing coupled with the analysis of multiple cancer genomics databases.
ACT Genomics NGS laboratory opens 08
Establishes bioinformatics platform 10
ACT Genomics Singapore branch opens 10
Acquires CAP (NGS) laboratory certification 04
ACT Genomics Hong Kong branch opens
ACT Genomics forms its subsidiary in Shanghai 09
Receives the Symbol of National Quality in Taiwan 12
ACT Genomics Japan branch opens
ACT Genomics receives Frost & Sullivan Product Line
Strategy Leadership Award (Molecular Diagnostics) 03
ACT Genomics enters into a joint venture with Canon Medical System Corporation named ACTmed 07
ACTOnco®+ receives National Innovation Award in Taiwan 12
ACTmed establishes an analysis laboratory named "Shonan iPark Laboratory" in "Shonan Health Innovation Park" in Kanagawa, Japan 04
ACT Genomics opens third laboratory in Asia at Hong Kong Science & Technology Park
ACT Genomics wins Taiwan Bio Industry Organization Awards- Emerging Company of the Year
ACT Genomics forms a collaboration with AIA Hong Kong to promote precision cancer medicine 07
ACT Genomics wins the Golden Torch Award of "Annual Top 10 Enterprise" in Taiwan 11
ACT Genomics wins 2019 National Innovation Award in Taiwan 12
ACT Genomics partners with Oncoshot to drive clinical trials at a strategic level in Singapore 03
ACT Genomics is the first to receive approval for laboratory-developed NGS tests and services (LDTS) in Taiwan 05
ACT Genomics and Nan Shan Life Insurance cooperate to promote high-quality cancer precision medicine services in Taiwan 09
ACT Genomics becomes a member of The Global Alliance For Genomics And Health (GA4GH)
ACT Genomics acquires ISO/IEC 27001 certification 11
ACT Genomics completes acquisition of MC Diagnostics
ACT Genomics HK Lab Limited acquires CAP Laboratory Certification 06
ACT Genomics receives 2021 Frost & Sullivan Best Practices Award 07
CerbACT Asia – a joint venture between ACT Genomics and Cerba Research – is formed to establish a new and top-notched facility in Taipei 08
ACT Genomics acquires Sanomics 11
ACT Genomics'Thailand subsidiary acquires ISO 15189:2012 accreditation 02
ACT Genomics'Thailand subsidiary acquires ISO 15190:2003 accreditation 04
Prenetics Global Limited (NASDAQ: PRE) acquires a majority stake in ACT Genomics Holdings Company Limited 12
ACT Genomics receives clearance from the U.S. Food and Drug Administration (FDA) for ACTOnco® 01
All of us at ACT Genomics are driven to make a difference in this battle against cancer by drawing on our experience from facing cancer at close range. Each of us are devoted to win this fight against cancer. Join us to transform science into actionable solutions!